Filing Details
- Accession Number:
- 0001181431-14-028432
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-06 16:27:51
- Reporting Period:
- 2014-08-06
- Filing Date:
- 2014-08-06
- Accepted Time:
- 2014-08-06 16:27:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1581720 | Loxo Oncology Inc. | LOXO | Pharmaceutical Preparations (2834) | 462996673 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1237289 | D Scott Sandell | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-08-06 | 1,558,651 | $0.00 | 1,558,651 | No | 4 | C | Indirect | See Note 2 |
| Common Stock | Acquisiton | 2014-08-06 | 230,769 | $13.00 | 1,789,420 | No | 4 | P | Indirect | See Note 2 |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Note 2 |
| No | 4 | P | Indirect | See Note 2 |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2014-08-06 | 1,558,651 | $0.00 | 1,558,651 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect |
Footnotes
- In connection with the consummation of the Issuer's initial public offering on August 6, 2014, each share of Series B Convertible Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration. The Series B Convertible Preferred Stock had no expiration date.
- The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.
- NEA 14 purchased these shares directly from the Issuer in a private placement.
Billionaire Hedge Funds
